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Background
Casitas-B-lineage lymphoma protein-b (Cbl-b), an E3
ubiquitin ligase, has been identified as a key intracellular
checkpoint limiting lymphocyte activation. Inhibiting
Cbl-b has been shown to enhance T cell and natural
killer cell mediated antitumor activity in mouse tumor
models. APN401 is a suspension of autologous peripheral
blood mononuclear cells (PBMCs) transfected with a
siRNA that knocks down Cbl-b. A Phase I clinical trial
has been initiated to establish feasibility and to determine
toxicity of the intravenous infusion of APN401.
Methods
Patients with metastatic solid tumors no longer respond-
ing to standard therapies have been enrolled into one of
three successive dosing cohorts in which they received a
single intravenous infusion of 5, 10, or 50 x105/kg trans-
fected PBMCs. Eligibility criteria included at least 4 weeks
since prior therapy, ECOG performance status 0-1, and
adequate hematologic and organ function. Patients with
active autoimmune disease or a requirement for immune
suppressive drugs were excluded. PBMCs were collected
by leukapheresis. The following day PBMCs were trans-
fected with Cbl-b siRNA ex vivo by electroporation and
then infused over 30 minutes.
Results
Three patients have been treated in each of the three
dosing cohorts. PBMCs were successfully collected and
transfected with Cbl-b siRNA in all patients, which
included 6 with pancreatic, 2 with colon, and 1 with
kidney cancers. Among PBMCs, CD56 cells were most
efficiently transfected (55%), followed by CD3 (46%),
CD19 (45%), and CD14 (23%) cells. Cbl-b-siRNA-
transfected PBMCs produced 4-fold more interferon
gamma and 2-fold more interleukin-2 in response to sti-
mulation with anti-CD3/CD28 antibody in vitro. APN401
infusions were well tolerated. One patient in the first,
three in the second, and two in the third cohort developed
grade 2 chills at the completion of the infusion. These
responded to meperidine. Grade 3 or 4 toxicities were not
observed. No immediate hypersensitivity was noted. There
was no evidence of autoimmune adverse effects. Patients
are being followed for systemic immune effects.
Conclusion
A single intravenous infusion of 50 x105/kg of APN401,
autologous Cbl-b silenced PBMCs, into patients with
refractory solid tumors is feasible and safe. The results
support Phase II clinical trials of multiple infusions of
APN401.
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